表皮生长因子受体单抗相关生物标志研究进展

表皮生长因子受体（EGFR）靶向药物的出现为恶性肿瘤的治疗提供了新的选择。研究表明，西妥昔单抗联合化疗治疗晚期结直肠癌及肺癌较单用化疗有效率提高10％～20％。然而EGFR单抗昂贵的价格及只对部分患者有效限制了其临床的合理应用，如能有效利用疗效预测生物标志，指导临床用药，不但能明显提高治疗有效率，避免患者不必要的不良反应，也能减少患者在经济及时间上的浪费。文章对相关预测生物标志的研究进行了较为深入的综述。

Study progress of EGFR-targeting antibody related biomarkers

With the emerging of EGFR-targeting antibody, there is a new choice for malignant tumors. Several studies indicate that cetuximab combined with chemotherapy have a role in the first-line treatment of metastatic colorectal and lung cancer, with a 10% to 20% absolute increase in response rates reported. But, cosily price and partly responsive rate restrict the reasonable use of the drug. If the predictive biomarker works, clinician can identify patients who can benefit from the regimen and relieve the economic and toxic burden of null patients and avoid wasting time and money. The study progress of the biomarkers related to EGFR-targeting antibody was reviewed.